New strategy to boost the effect of immunotherapy in the most aggressive form of lung cancer
Inhibiting a specific gene, MET, in combination with standard chemotherapy and immunotherapy, enhances treatment efficacy and limits tumor growth in small cell lung cancer (SCLC)
2025-08-12
(Press-News.org)
Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research Institute, in collaboration with researchers from the CIBERONC cancer research network. The study, published in Cell Reports Medicine, highlights the role of HGF (hepatocyte growth factor)—which is linked to cell proliferation and survival—in the poor prognosis of this disease and its resistance to treatment. The research explores a novel approach that adds a MET inhibitor to standard therapy and demonstrates improved treatment response.
Small cell lung cancer is one of the most aggressive types of lung cancer. Although it accounts for only 15% of all lung cancers, its three-year survival rate is just 15%, due to its rapid progression and late diagnosis, which usually excludes surgical options. The current treatment consists of a combination of chemotherapy and immunotherapy, but SCLC is known for its strong ability to develop resistance and metastasize. However, this new study opens a promising pathway for tackling the disease.
“We observed that combining immunotherapy and chemotherapy with a MET inhibitor makes immunotherapy more effective, increasing both survival and tumor response in mouse models,” explains Dr. Edurne Arriola, lead author of the study, researcher in the Cancer Molecular Therapy Research Group, Head of the Lung Cancer Section at the Hospital del Mar Medical Oncology Department, and researcher at CIBERONC. This study represents the culmination of more than ten years of research.
A Boost for Immunotherapy
The study analyzed the response to various treatment combinations in mouse models of small cell lung cancer. One group served as the untreated control, another received chemotherapy alone, a third group was treated with chemotherapy and immunotherapy using an anti-PD-L1 monoclonal antibody, and the final group received chemotherapy, immunotherapy, and a MET inhibitor. The best results, in terms of both tumor progression and mouse survival, were observed in the group treated with the MET inhibitor in addition to chemotherapy and immunotherapy. In fact, six out of nine tumors treated with this combination showed a complete response.
Dr. Arriola notes that “this strategy slowed tumor growth and in some cases, completely suppressed it. When we analyzed survival and tumor progression, mice treated with the MET inhibitor had better survival outcomes.” This positive and long-lasting response is attributed to the inhibitor’s ability to counteract the MET gene’s influence on the tumor microenvironment. When MET is inhibited, “the tumor microenvironment—which contributes to treatment resistance—changes, making it easier for immune system T cells, activated by immunotherapy, to act,” she adds. In other words, the inhibitor does not act directly on the tumor, but rather facilitates the effectiveness of standard treatment.
The researchers validated their findings using human tumor samples. They observed that in cases where the MET gene is overexpressed, patients have a worse prognosis, with a tumor microenvironment that impairs the effectiveness of immunotherapy and contributes to greater treatment resistance. The same phenomenon was noted with chemotherapy. This is a relevant discovery, as half of the patients with this type of tumor show MET overexpression.
The next step is to initiate a clinical trial in SCLC patients. The goal is to determine whether adding the MET inhibitor after the initial chemotherapy and immunotherapy phase, during maintenance treatment with immunotherapy alone, can prevent tumor progression.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-08-12
There are more than 15,000 cattle and hog feeding operations in the United States. These operations rear 70% of the country's cattle and 98% of its hogs.
Now, for the first time in the nation's history, we know with certainty where most of them are, thanks to research from the University of Michigan.
The research team found that a quarter of the nation's hog and cattle feeding operations are found in just 30 counties out of more than 3,000 in the United States. Going a step further, the team also found that an air pollutant linked to heart and respiratory issues near these animal feeding operations, ...
2025-08-12
Graphite has attracted global interest due to its unique anisotropic properties, including excellent electrical and thermal conductivity. Widely used as a battery anode material and in applications such as electromagnetic shielding, catalysis, and nuclear technology, graphite remains a critical material in both industrial and research fields.
For decades, researchers have sought to produce high-quality artificial graphite with large grains and smooth, layered structures. Conventional methods typically involve high-temperature treatment of polymer ...
2025-08-12
They’ve survived for billions of years in boiling acid, deep-sea vents and salt flats. Now, some of Earth’s oldest life forms — microbes called Archaea — are offering a new weapon in the fight against one of today’s most urgent health threats: antibiotic resistance.
In a new study published in Nature Microbiology, researchers at the University of Pennsylvania used artificial intelligence to identify previously unknown compounds in Archaea that could fuel the development ...
2025-08-12
A research team headed by the University of Zurich has developed a powerful new method to precisely edit DNA by combining cutting-edge genetic engineering with artificial intelligence. This technique opens the door to more accurate modeling of human diseases and lays the groundwork for next-generation gene therapies.
Precise and targeted DNA editing by small point mutations as well as the integration of whole genes via CRISPR/Cas technology has great potential for applications in biotechnology and gene therapy. However, it is very important that the so-called “gene scissors” do not cause any unintended ...
2025-08-12
New method to synthesize carbohydrates could pave the way to biomedical advances
(Santa Barbara, Calif.) — Carbohydrate is a familiar term. It’s the bagel you had for breakfast, the bread in your sandwich, the slice of cake you’re thinking about sneaking later today. But carbs aren’t only in baked goods, and they’re not just found in foods. Small yet structurally complex carbohydrates serve as elements of cell walls and are important in intercellular interactions.
Scientists can quickly and reliably make many biomolecules, from DNA to proteins, using automated instruments. So it may come as a surprise that for decades, scientists have had major difficulty ...
2025-08-12
Plants transport water and nutrients from their environment through specialised pores. Researchers at the University of Geneva (UNIGE) have shed light on a little-known but essential mechanism for proper plant function: the directionality of nutrient transport in roots. The team demonstrates that this transport becomes unidirectional as the root develops. This discovery highlights the central role of the pores connecting plant cells and opens up new perspectives for improving plant resistance to water stress. These findings are published in the journal Molecular Plant.
Roots play ...
2025-08-12
Scientists at Tsinghua University have developed a method to grow kidney tumours in the lab using cells from real patients, offering a potential new tool in the fight against renal cancer. Their research, published in the journal Biofabrication, outlines how 3D bioprinting technology can be used to replicate the unique characteristics of each patient’s tumour.
The team combined tumour cells with other cell types, including blood vessel-like structures, to mimic the environment within the body. The lab-grown tumours, called organoids, are created from real patients’ tumour cells, and exactly mimic their traits. ...
2025-08-12
Cats with dementia have brain changes similar to those of people with Alzheimer’s disease, offering a valuable model for studying the condition in humans, a study says.
Scientists discovered a build-up of the toxic protein amyloid-beta in the brains of cats with the condition – one of the defining features of Alzheimer’s disease.
The findings offer a clearer picture of how amyloid-beta may lead to age-related brain dysfunction and memory loss in cats, experts say.
Many older cats develop dementia, leading to behavioural changes such as increased vocalisation – or meowing – confusion and disrupted sleep ...
2025-08-12
Cancer of the voice box or larynx is an important public health burden. In 2021, there were an estimated 1.1 million cases of laryngeal cancer worldwide, and approximately 100,000 people died from it. Risk factors include smoking, alcohol abuse, and infection with human papillomavirus. The prognosis for laryngeal cancer ranges from 35% to 78% survival over five years when treated, depending on the tumor’s stage and its location within the voice box.
Catching cancer early is key for a patient’s prospects. At present, laryngeal cancers are diagnosed through video nasal endoscopy and biopsies ...
2025-08-12
COLUMBUS, Ohio – Parents and caregivers often hear a child say, “I don’t want to go to school.” But when this becomes a regular occurrence, it may be a sign of school avoidance, also known as school refusal- which may be a sign of emotional distress. A new national survey conducted by Ipsos on behalf of The Kids Mental Health Foundation, founded by Nationwide Children’s Hospital, reveals nearly a third of parents (30%) whose child missed school due to fear or anxiety last year report their child missed more than a week of school.
The national survey of more than 1,000 parents across the United States also reveals roughly ...
LAST 30 PRESS RELEASES:
[Press-News.org] New strategy to boost the effect of immunotherapy in the most aggressive form of lung cancer
Inhibiting a specific gene, MET, in combination with standard chemotherapy and immunotherapy, enhances treatment efficacy and limits tumor growth in small cell lung cancer (SCLC)
